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AbstrAct
Objectives tofacitinib is an oral Janus kinase inhibitor for 
treatment of psoriatic arthritis (Psa). We evaluated patient-
reported outcomes (PrOs) in patients with Psa refractory to 
≥1 conventional synthetic disease-modifying antirheumatic 
drug (csDMarD-ir) and tumour necrosis factor inhibitor-
naïve in a 12-month, phase iii randomised controlled trial 
(OPal Broaden [nct01877668]).
Methods Patients (n=422) received tofacitinib 5 mg or  
10 mg twice daily, adalimumab 40 mg subcutaneously every 
2 weeks or placebo advancing to tofacitinib 5 mg or 10 mg 
twice daily at month 3. least squares mean changes from 
baseline and percentages of patients reporting improvements 
≥minimum clinically important differences (MciD); and scores 
≥normative values in: Patient global assessment of disease 
activity (Ptga), Pain, Patient global Joint and Skin assessment 
(PgJS), Short Form-36 Health Survey version 2 (SF-36v2), 
Functional assessment of chronic illness therapy-Fatigue 
(Facit-Fatigue), euroQol 5-Dimensions-3-level questionnaire 
(eQ-5D-3l) and ankylosing Spondylitis Quality of life (aSQol) 
were determined. nominal p values were cited without 
multiple comparison adjustments.
Results at month 3, Ptga, Pain, PgJS, Facit-Fatigue,  
eQ-5D-3l, aSQol and SF-36v2 Physical component 
Summary (PcS), physical functioning (PF), bodily pain 
(BP) and vitality domain scores exceeded placebo 
with both tofacitinib doses (p≤0.05); SF-36v2 social 
functioning with 5 mg twice daily (p≤0.05). Percentages 
reporting improvements ≥MciD in Ptga, Pain, PgJS, 
Facit-Fatigue, aSQol and SF-36v2 PcS, PF, BP and 
general health scores exceeded placebo with both 
tofacitinib doses (p≤0.05) and were similar with 
adalimumab.
Conclusion csDMarD-ir patients with active Psa reported 
statistically and clinically meaningful improvements in PrOs 
with tofacitinib compared with placebo at Month 3.
InTROduCTIOn
Psoriatic arthritis (PsA) has multiple manifes-
tations including inflammation of peripheral 
joints, tendons, ligaments, skin and the axial 
skeleton.1 PsA is associated with considerable 
disease burden including fatigue, impaired 
Key messages
What is already known about this subject?
 ► tofacitinib at 5 mg and 10 mg twice daily is effective 
for the treatment of patients with psoriatic arthritis 
(Psa) and improves quality of life and function in 
addition to improving the signs and symptoms of the 
disease.
What does this study add?
 ► in this post hoc analysis of patients with Psa and an 
inadequate response to conventional synthetic dis-
ease-modifying antirheumatic drugs (csDMarD-ir), 
patient-reported outcomes (PrOs) improved with 
tofacitinib, compared with placebo, at month 3; 
many improvements were greater than the min-
imum clinically important differences, with low 
numbers needed to treat, particularly in those PrOs 
most impacted by Psa, as well as values that met or 
exceeded normative scores.
 ► these improvements were reported within 2–4 weeks 
and were maintained to month 12.
How might this impact on clinical practice?
 ► these results demonstrate that tofacitinib provides 
significant and clinically meaningful improvements 
across a range of PrOs in csDMarD-ir patients with 
Psa, further supporting its use in clinical practice.
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physical function and health-related quality of life 
(HRQoL), increased healthcare costs and reduced work 
productivity.2–5
Patient-reported outcomes (PROs) measure PsA-spe-
cific skin and joint disease activity by Patient Global 
Assessment of disease activity (PtGA); pain, fatigue and 
physical function by the Health Assessment Question-
naire Disability Index (HAQ-DI); and HRQoL by generic 
Short Form-36 Health Survey (SF-36), EuroQol 5-Dimen-
sions-3-level questionnaire (EQ-5D-3L) and Dermatology 
Life Quality Index (DLQI).6–10 The importance of PROs 
assessing treatment responses is reflected in the updated 
2016 PsA core domain set, developed by the Group 
for Research and Assessment of Psoriasis and Psoriatic 
Arthritis-Outcome Measures in Rheumatology (GRAP-
PA-OMERACT) working group, which has defined a core 
set of outcome domains to be measured in randomised 
controlled trials (RCTs) and longitudinal observational 
studies.11
Tofacitinib is an oral Janus kinase (JAK) inhibitor for 
the treatment of PsA. The efficacy and safety of tofacitinib 
5 mg and 10 mg twice daily have been demonstrated in 
two phase III RCTs of 6–12 months’ duration in patients 
with inadequate responses to conventional synthetic 
disease-modifying antirheumatic drugs (csDMARD-IR) 
or tumour necrosis factor inhibitors (TNFi-IR) with active 
PsA (OPAL Broaden: NCT01877668; OPAL Beyond: 
NCT0188243912 13) and an ongoing long-term extension 
(LTE) study (OPAL Balance: NCT01976364).
The objective of these analyses was to evaluate the effect 
of tofacitinib on PROs in csDMARD-IR patients with PsA 
enrolled in OPAL Broaden to assess if reported improve-
ments were considered meaningful14–16 by evaluating 
the percentages of patients reporting improvements 
≥minimum clinically important differences (MCIDs) and 




OPAL Broaden was a phase III RCT conducted in 
126 centres worldwide between January 2014 and December 
2015.12 Briefly, eligible patients were: ≥18 years; with a 
diagnosis of PsA for ≥6 months; fulfilled the ClASsification 
criteria for Psoriatic ARthritis17; with active plaque psoriasis 
at screening; and active arthritis (≥3 swollen and ≥3 tender 
joints) at screening and baseline. Key inclusion and exclu-
sion criteria were published previously.12
Eligible patients were randomised 2:2:2:1:1 to tofacitinib 
5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab 
40 mg subcutaneous injection once every 2 weeks, placebo 
advancing to tofacitinib 5 mg twice daily at month 3 or 
placebo advancing to tofacitinib 10 mg twice daily at month 
3. Patients received a stable background dose of a single 
csDMARD (methotrexate: 83.6%; sulfasalazine: 9.2%; 
leflunomide: 5.7%; hydroxychloroquine: 0.2%; other: 
1.2%) and were followed up to month 12.
Assessment of PROs
PROs were assessed up to month 12. MCIDs were defined 
based on previously published changes; improvements ≥10 
mm (decrease from baseline) were considered MCID for all 
visual analogue scale (VAS) scores. PtGA-VAS and Pain-VAS 
(range 0–100 mm)6 18 were evaluated at baseline, week 2 
and months 1, 2, 3, 4, 6, 9 and 12. The following PROs 
were evaluated at baseline and months 1, 3, 6, 9 and 12: 
Patient Global Joint and Skin Assessment (PGJS) arthritis 
and psoriasis score and also separate joint and skin scores 
due to the potential divergence in the self-assessment of 
joint and skin disease activities, each evaluated by VAS6; 
SF-36 version 2 (SF-36v2) Physical Component Summary 
(PCS) and Mental Component Summary (MCS) scores 
(MCIDs: PCS and MCS: improvements ≥2.5 points) and 
eight domain scores (norm-based scale; higher scores indi-
cating better HRQoL; physical functioning [PF], role phys-
ical [RP], bodily pain [BP], general health [GH], vitality 
[VT], social functioning [SF], role emotional, mental 
health [MH]; MCID for all domain scores: improvements 
≥5.0 points)9 19 20; Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-Fatigue) Total score (range 0–52; 
higher scores indicating less fatigue; MCID: improvements 
≥4.0 points)21; EQ-5D-3L dimension scores (Mobility, Self-
care, Usual activities, Pain/discomfort, Anxiety/depres-
sion [range 1–3; higher score indicates poorer HRQoL]) 
and EQ-VAS10 22; and Ankylosing Spondylitis Quality of 
Life (ASQoL; range 0–18; higher scores indicate poorer 
HRQoL [eg motivation, daily activities, mood independ-
ence, social interactions; higher scores indicate poorer 
HRQoL]; MCID: improvements ≥1.8 points).23
PtGA, Pain, SF-36v2, EQ-5D-3L, FACIT-Fatigue and 
ASQoL were secondary outcome measures, and SF-36v2 
PF domain and FACIT-Fatigue were key secondary effi-
cacy endpoints at month 3. In addition, HAQ-DI (range 
0–3; higher scores indicate greater functional impair-
ment; MCID: improvements ≥0.35 points) mean change 
from baseline, DLQI and Itch Severity Item (ISI) were 
measured. HAQ-DI responses have been reported previ-
ously,12 and DLQI and ISI results that will form the basis 
of a future publication are not reported here.
statistical analysis
For continuous endpoints, least squares mean changes 
from baseline were compared between active treatments 
(tofacitinib 5 mg and 10 mg twice daily and adalimumab 
40 mg subcutaneous injection once every 2 weeks) and 
the combined placebo group, using a repeated meas-
ures model with the fixed effects of treatment, visit, treat-
ment-by-visit interaction, geographic location and base-
line values, without imputation for missing values. An 
unstructured covariance model was used. The two placebo 
sequences were combined into a single placebo group up 
to month 3 (the end of the placebo-controlled period). P 
values were calculated from these repeated measures anal-
yses. For results after month 3, a second repeated measures 
model was used including visits up to the end of study for 
all treatment sequences. For binary endpoints, p values 
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were calculated for comparing percentages between treat-
ment groups, based on the normal approximation for the 
difference in binomial percentages. The same method 
was used to analyse the percentage of patients reporting 
scores ≥normative values. Missing values were not imputed, 
except for the percentage of patients reporting improve-
ments ≥0.35 (MCID) in HAQ-DI, where non-responder 
imputation was prespecified for this efficacy measure. 
Nominal p values for the differences between active treat-
ment versus placebo were reported without adjustment for 
multiplicity. For all endpoints, significance was set at p≤0.05 
throughout.
For illustrative purposes and to facilitate viewing improve-
ments in HRQoL simultaneously across eight domains,24 
spydergrams were generated using SF-36v2 domain raw 
scores (range 0–100), where published age–gender norms 
were matched to the study population for a benchmark 
comparison. Based on MCID response rates, the number 
needed to treat (NNT) was also calculated, defined as the 
inverse of the difference between PRO response rates in 
active treatment (tofacitinib 5 mg or 10 mg twice daily or 
adalimumab) and placebo groups at month 3.25 A separate 
analysis included the percentages of patients reporting scores 
≥normative values, with ‘normative’ referring to responses 
in individuals in the US general population without chronic 
disease. The percentages of patients reporting scores 
≥normative values were calculated for SF-36v2 PCS, MCS 
and norm-based domain scores, FACIT-Fatigue and HAQ-DI 
(normative values: SF-36v2 PCS, MCS and domain scores 
≥50; FACIT-Fatigue Total score ≥40.1; and HAQ-DI ≤0.2526).
Pearson correlation coefficients (|r|) were also assessed 
at month 3 with particular interest in the following PROs: 
HAQ-DI and SF-36v2 PF domain; Pain and SF-36v2 BP 
domain and EQ-5D-3L pain/discomfort dimension. 
Correlations between FACIT-Fatigue Total score and 
SF-36v2 VT domain have been evaluated and will be 
published in a future publication. Statistical significance 
for testing the null hypothesis of Pearson correlations 
equal to zero was assessed based on Student’s t distribu-
tion (N-2 degree of freedom, where N is the total number 
of patients in the analysis). The analysis included patients 
with observations at a visit of interest in the Full Analysis 
Set.
ResulTs
Patient demographics and disease characteristics
In total, 422 patients were randomised and received 
≥1 dose of the study drug; 373 patients completed the 
study. Baseline patient demographics, reported previ-
ously, were broadly similar across treatment groups12; 
the majority were Caucasian (96.9%), female (53.3%), 
with a mean age of 47.9 (SD 12.1) years and mean 
disease duration 6.1 (SD 6.5) years.
PROs
Baseline PROs were similar across treatment groups 
(table 1). Significant improvements from baseline 
were reported at month 3 with all active treatments in 
PtGA, Pain, HAQ-DI, PGJS, SF-36v2 PCS, PF, BP and VT 
domains (tofacitinib 5 mg and 10 mg twice daily only), 
FACIT-Fatigue (Total score and two domain scores), 
EQ-5D-3L (mobility and pain/discomfort dimension 
scores), EQ-VAS and ASQoL, compared with placebo (all 
p≤0.05; table 1).
PtGA, Pain and PGJs
As early as week 2 (the first post-baseline assessment), 
greater improvements from baseline in PtGA and Pain 
were reported by patients receiving tofacitinib 5 mg 
and 10 mg twice daily, compared with placebo, and 
maintained to month 3 (all p≤0.05 for both compari-
sons; figure 1A,B). Greater improvements from base-
line were reported in PGJS as early as month 1 (the first 
post-baseline assessment) with both tofacitinib doses, 
compared with placebo, and were maintained to month 
3 (all p<0.01 for both comparisons; figure 1C). Patients 
receiving adalimumab also reported significant improve-
ments in PtGA, Pain and PGJS to month 3 (all p<0.01; 
figure 1). Responses in PROs in those receiving active 
treatments were generally maintained to month 12; 
patients receiving placebo who advanced to tofacitinib at 
month 3 reported similar improvements in PtGA, Pain 
and PGJS after switching to tofacitinib (figure 1).
The percentages of patients reporting clinically mean-
ingful improvements (≥MCID) at month 3 exceeded 
placebo with all active treatments, compared with 
placebo, for PtGA, Pain and PGJS (all p≤0.05). NNT 
values were similar across active treatments (figure 2A).
sF-36v2 PCs, MCs and domain scores
Patients receiving all active treatments reported improved 
SF-36v2 PCS scores compared with placebo at month 1, 
maintained to month 3 (all p≤0.05; figure 3A). No improve-
ments in SF-36v2 MCS were reported at month 3 versus 
placebo (table 1). Patients receiving placebo who advanced 
to tofacitinib 5 mg or 10 mg twice daily at month 3 reported 
similar improvements in SF-36v2 PCS scores post-month 3 
(figure 3A).
Significant improvements in SF-36v2 PF, BP and VT 
domain scores following treatment with both tofacitinib 
doses, compared with placebo, were reported at month 3 
(all p≤0.05; table 1). Improvements in SF domain scores 
were reported following tofacitinib 5 mg twice daily at 
month 3, versus placebo (p≤0.05; table 1).
Compared with placebo, patients receiving adalim-
umab reported significant improvements in SF-36v2 PF, 
BP and GH domains (all p≤0.05) at month 3 (table 1). 
Responses reported by patients receiving tofacitinib or 
adalimumab were generally maintained to month 12.
Spydergrams of SF-36v2 domains (raw 0–100 scale) 
illustrate that reported improvements from baseline to 
month 3 in SF-36v2 domain scores were greater with both 
doses of tofacitinib and adalimumab (OPAL Broaden) 
than placebo (figure 3B).
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Figure 1 Least squares mean (LSM) changes from baseline: (A) Patient Global Assessment of disease activity visual analogue 
scale (PtGA-VAS) (mm); (B) Pain-VAS (mm); (C) Patient Global Joint and Skin Assessment (PGJS)-VAS (mm) arthritis and 
psoriasis. *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; results up to month 3 were based on a repeated-measures 
model including data up to month 3 for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab  
40 mg subcutaneous injection once every 2 weeks and combined placebo group. Results after month 3 were based on a 
second repeated-measures model including data up to end of study for the five treatment sequences (tofacitinib 5 mg twice 
daily, tofacitinib 10 mg twice daily, adalimumab 40 mg subcutaneous injection once every 2 weeks, placebo → tofacitinib 5 mg 
twice daily and placebo → tofacitinib 10 mg twice daily), reporting results after month 3 only. Missing values were not imputed. 
Patient N is number of subjects evaluable at each visit. BID, twice daily; SC Q2W, subcutaneous injection once every 2 weeks.
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Figure 2 Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and 
number needed to treat (NNT) in (A) patient-reported outcomes (PROs); (B) Short Form-36 health survey version 2 (SF-36v2) 
domain scores at month 3 and percentages of patients reporting scores ≥normative values in (C) PROs; (D) SF-36v2 domain 
scores, at baseline and month 3. *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; p values were based on the normal 
approximation for the difference in binomial percentages without imputation for missing values (except Health Assessment 
Questionnaire Disability Index [HAQ-DI] MCID response, which used non-responder imputation); N is the number of patients 
per group in the Full Analysis Set; the number of patients evaluable for each PRO endpoint may be fewer than N; MCID cut-
offs: Patient Global Assessment of disease activity visual analogue scale (PtGA-VAS) decrease from baseline ≥10 mm; Pain-
VAS decrease from baseline ≥10 mm; Patient Global Joint and Skin Assessment (PGJS)-VAS decrease from baseline ≥10 
mm; SF-36v2: Physical Component Summary (PCS) and Mental Component Summary (MCS) increase from baseline ≥2.5, 
SF-36v2 domain scores increase from baseline ≥5.0; Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) 
increase from baseline ≥4.0; Ankylosing Spondylitis Quality of Life (ASQoL) decrease from baseline ≥1.8; HAQ-DI decrease 
from baseline ≥0.35; MCIDs are defined here in terms of mean change from baseline to month 3 in a treatment group; NNT 
calculated by the inverse of the percentage of patients receiving active treatments reporting improvements ≥MCIDs minus 
the percentage of patients in the placebo group reporting improvements ≥MCIDs; the percentage of patients reporting scores 
≥normative values: HAQ-DI ≤0.25, FACIT-Fatigue Total score ≥40.1, SF-36v2 each of the component summary and domain 
scores ≥50. BID, twice daily; BP, bodily pain; GH, general health; MH, mental health; NA, not available; PF, physical functioning; 
RE, role emotional; RP, role physical; SC Q2W, subcutaneous injection once every 2 weeks; SF, social functioning; VT, vitality.
The percentages of patients reporting improvements 
≥MCID at month 3 with all active treatments exceeded 
placebo in PCS, PF, BP and GH domains (all p≤0.05). 
In addition, improvements ≥MCID in MH domain scores 
were reported with tofacitinib 10 mg twice daily (p≤0.05). 
NNTs were similar across active treatments (figure 2A,B).
The percentages of patients reporting scores ≥norma-
tive values were numerically higher with both tofaci-
tinib doses versus placebo in SF-36v2 PCS, MCS and 
all domain scores (figure 2C,D). Significantly more 
patients receiving tofacitinib 5 mg twice daily reported 
scores ≥normative values in MCS, BP and SF domains 
compared with placebo (all p≤0.05). Significantly more 
patients receiving tofacitinib 10 mg twice daily reported 
scores ≥normative values in PCS, PF, BP, GH, SF and MH 
domains than placebo (all p≤0.05). Similar results were 
reported by patients receiving adalimumab.
FACIT-Fatigue Total score and AsQol
Greater improvements from baseline in FACIT-Fatigue 
Total score were reported at month 1 following tofacitinib 
5 mg twice daily versus placebo. At month 3, greater 
improvements from baseline in FACIT-Fatigue Total score 
were reported by patients receiving both tofacitinib doses, 
compared with placebo (all p≤0.05; figure 4A). Improve-
ments in ASQoL exceeded placebo at month 1 with both 
doses of tofacitinib, sustained to month 3 (all p<0.01; 
figure 4B). Patients receiving adalimumab also reported 
significant improvements in FACIT-Fatigue and ASQoL 
at month 3, compared with placebo (p≤0.05; figure 4A). 
Improvements in FACIT-Fatigue and ASQoL with all 
active treatments were generally maintained to month 12. 
Patients receiving placebo who advanced to tofacitinib 
5 mg or 10 mg twice daily at month 3 reported improve-
ments in FACIT-Fatigue and ASQoL post-month3.
The percentage of patients reporting improvements 
≥MCID in FACIT-Fatigue at month 3 were greater with 
both tofacitinib doses (p≤0.05) but not with adalim-
umab versus placebo; NNTs were similar across active 
treatments (figure 2A). A greater percentage of patients 
reported improvements in ASQoL ≥MCID at month 
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Figure 3 (A) Least squares mean (LSM) change from baseline in Short Form-36 health survey version 2 (SF-36v2) Physical 
Component Summary (PCS) score; and (B) spydergram of domain scores from baseline to month 3 and versus age-matched 
and gender-matched norms. Panel A: *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; results up to month 3 were 
based on a repeated measures model including data (norm-based) up to month 3 for tofacitinib 5 mg twice daily, tofacitinib 
10 mg twice daily, adalimumab 40 mg subcutaneous injection once every 2 weeks and combined placebo group. Results 
after month 3 were based on a second repeated measures model including data up to end of study for the five treatment 
sequences (tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab 40 mg subcutaneous injection once every 
2 weeks, placebo → tofacitinib 5 mg twice daily and placebo → tofacitinib 10 mg twice daily), reporting results after month 3 
only. Missing values were not imputed. Dashed line indicates end of placebo-controlled period. N represents the number of 
subjects evaluable at each visit. Panel B: *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; spydergrams were generated 
using domain raw scores (range 0–100); US age–gender norms were matched to the protocol population; spydergrams are for 
illustrative purposes only; p values were generated using a repeated measures model for comparisons with placebo based on 
LSM changes from baseline in domain norm-based scores at month 3 (table 1). Missing values were not imputed. BID, twice 
daily; BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role emotional; RP, role physical;  
SC Q2W, subcutaneous injection once every 2 weeks; SF, social functioning; VT, vitality.
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Figure 4 Least squares mean (LSM) changes from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue 
(FACIT-Fatigue) Total score and (B) Ankylosing Spondylitis Quality of Life (ASQoL). *p≤0.05, **p<0.01, ***p<0.001 compared with 
placebo; results up to month 3 were based on a repeated measures model including data up to month 3 for tofacitinib  
5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab 40 mg subcutaneous injection once every 2 weeks and combined 
placebo group. Results after month 3 were based on a second repeated measures model including data up to end of study 
for the five treatment sequences (tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, adalimumab 40 mg subcutaneous 
injection once every 2 weeks, placebo → tofacitinib 5 mg twice daily and placebo → tofacitinib 10 mg twice daily), reporting 
results after month 3 only. Missing values were not imputed. N is the number of subjects evaluable at each visit. BID, twice 
daily; SC Q2W, subcutaneous injection once every 2 weeks.
9Strand V, et al. RMD Open 2019;5:e000806. doi:10.1136/rmdopen-2018-000806
Psoriatic arthritis
Table 2 Correlation analyses of PRO endpoints at month 3
HAQ-DI SF-36v2† PF SF-36v2† BP Pain-VAS EQ-5D-3L P/D
Tofacitinib 5 mg twice daily (N=101) 
  HAQ-DI 1 −0.67 −0.61 0.55 0.33
  SF-36v2† PF – 1 0.64 −0.56 −0.38
  SF-36v2† BP – – 1 −0.70 −0.50
  Pain-VAS – – – 1 0.42
  EQ-5D-3L P/D – – – – 1
Tofacitinib 10 mg twice daily (N=103) 
  HAQ-DI 1 −0.85 −0.68 0.58 0.46
  SF-36v2† PF – 1 0.68 −0.52 −0.43
  SF-36v2† BP – – 1 −0.65 −0.60
  Pain-VAS – – – 1 0.42
  EQ-5D-3L P/D – – – – 1
Adalimumab 40 mg subcutaneous injection once every 2 weeks (N=100) 
  HAQ-DI 1 −0.83 −0.71 0.67 0.53
  SF-36v2† PF – 1 0.74 −0.63 −0.61
  SF-36v2† BP – – 1 −0.74 −0.70
  Pain-VAS – – – 1 0.58
  EQ-5D-3L P/D – – – – 1
Placebo (N=102) 
  HAQ-DI 1 −0.76 −0.66 0.58 0.36
  SF-36v2† PF – 1 0.72 −0.57 −0.44
  SF-36v2† BP – – 1 −0.58 −0.39
  Pain-VAS – – – 1 0.34
  EQ-5D-3L P/D – – – – 1
All correlations were **p<0.01, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; the 
analysis included patients with observations at a visit of interest in the Full Analysis Set; N is the number of patients included in calculating 
the sample correlation.
†SF-36v2 scores are norm-based.
BID, twice daily; BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions 3-level questionnaire; HAQ-DI, Health Assessment Questionnaire 
Disability Index; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; SF-36v2, Short Form-36 Health Survey 
version 2; VAS, visual analogue scale.
3 with all active treatments versus placebo (all p≤0.05; 
figure 2A).
The percentages of patients reporting scores ≥norma-
tive values were numerically higher with both tofacitinib 
doses compared with placebo for FACIT-Fatigue but not 
significant for either tofacitinib dose. In contrast, signifi-
cantly more patients receiving adalimumab, compared 
with placebo, reported scores ≥normative values in 
FACIT-Fatigue (p<0.01; figure 2C).
Correlation analysis
Correlations of pre-selected PRO endpoints (based on 
subject matter knowledge and clinical rationale) are 
shown in table 2. HAQ-DI at month 3 was moderately 
correlated (|r| >0.30–≤0.70) with Pain and EQ-5D-3L 
pain/discomfort dimension for all treatment groups. 
HAQ-DI was also moderately or highly (|r| >0.60) nega-
tively correlated with SF-36v2 PF and BP domains (all 
treatment groups). At month 3, Pain and the SF-36v2 BP 
domain were moderately or highly negatively correlated 
for all treatment groups. Correlations between SF-36v2 
PF and BP domains were moderate for both tofacitinib 
doses and placebo, and high for adalimumab.
These results are similar to previously reported correla-
tions between PROs in PsA and rheumatoid arthritis 
(RA).27–31
dIsCussIOn
In this study, patients with PsA who were refractory to 
csDMARDs reported improved PROs following treat-
ment with tofacitinib 5 mg and 10 mg twice daily versus 
placebo at month 3, which were generally maintained to 
month 12. At month 3, clinically meaningful NNTs ≤10 
were reported for PtGA, Pain, PGJS, SF-36v2 PCS and PF, 
BP and GH domain scores, FACIT-Fatigue Total score and 
HAQ-DI. NNTs provide an estimate of treatment effec-
tiveness by determining the number of patients needed 
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to treat in order to have one additional patient to benefit 
from the treatment relative to placebo.32 NNTs were 
similar with tofacitinib 5 mg and 10 mg twice daily and 
also with adalimumab, demonstrating that both tofac-
itinib doses were similar to the active control. In addi-
tion, correlations between preselected PRO endpoints 
were similar to previously reported correlations between 
PROs in PsA.28–31 All the PRO endpoints included in the 
correlation analysis were moderately or highly corre-
lated, implying that these improvements are important 
and consistent with successful treatment. Furthermore, 
simultaneous assessment of SF-36v2 domain scores using 
spydergrams demonstrated that multiple domains were 
improved compared with baseline; however, domain 
scores were lower than age–gender norms matched to 
the protocol population.
Many RCTs have assessed PROs in csDMARD-IR 
patients with PsA. In previous phase II and phase III 
RCTs of apremilast, significant improvements in clinical 
outcomes and HRQoL were observed.28 33 An RCT of goli-
mumab in csDMARD-IR patients with PsA reported signif-
icant improvements in HAQ-DI, HRQoL and productivity 
compared with placebo at month 6 that were sustained 
through to month 24. These improvements correlated with 
clinical improvement.34 Furthermore, in the Rheumatoid 
Arthritis PreventIon of structural Damage (RAPID)-PsA 
RCT, patients with active PsA treated with certolizumab 
pegol reported clinically meaningful differences in 
HAQ-DI, SF-36v2, fatigue (measured using the Fatigue 
Assessment Scale), Pain and DLQI at month 6, compared 
with placebo, but no correlation with clinical efficacy was 
observed.35 In addition, in the phase III FUTURE 1 RCT, 
patients with PsA receiving secukinumab reported signifi-
cant improvements in PtGA, Pain and FACIT-Fatigue after 
24 weeks of treatment.36 However, unlike OPAL Broaden, 
these studies did not include an active control, and an 
important finding of this analysis was that improvements in 
PROs reported by patients treated with tofacitinib 5 mg or 
10 mg twice daily were similar to those reported by patients 
receiving adalimumab 40 mg subcutaneous injection once 
every 2 weeks.
Fatigue is commonly reported by patients with PsA and 
was recently added to the PsA core domain set.21 37 38 In 
this analysis, NNTs for FACIT-Fatigue Total scores were 
lower than those for SF-36v2 VT domain and, impor-
tantly, similar to NNTs based on reported improvements 
in PtGA, PGJS and Pain at month 3.
Patients with PsA report impairment of PF, BP and VT. 
However, in comparison with patients with RA, patients 
with PsA are less likely to report impairments in RP and 
VT but are more likely to report difficulties in social, 
mental and emotional functioning, possibly due to the 
skin lesions that affect patients with PsA.20 39 40 Similar 
percentages of patients reported SF-36v2 scores ≥norma-
tive values with tofacitinib and adalimumab at month 
3. Compared with placebo, the percentages of patients 
reporting scores ≥normative values with either tofaci-
tinib dose were significant for SF-36v2 PCS, MCS and PF, 
BP, GH, SF and MH domains, thus demonstrating that 
patients receiving tofacitinib are more likely to attain 
function, fatigue and HRQoL scores comparable with 
those without arthritis or other chronic conditions than 
those receiving placebo.
Some differences in PROs were reported by patients 
receiving tofacitinib, compared with those receiving 
adalimumab. However, these active treatments have 
different modes of action (JAK inhibition and TNF inhi-
bition, respectively),41 42 with distinct effects on down-
stream intracellular signalling pathways that are likely to 
be complex and multifactorial.43 44 Therefore, it is diffi-
cult to isolate the specific processes or pathways affected 
by JAK inhibition and TNF inhibition that give rise to 
differences in PROs in patients receiving tofacitinib and 
adalimumab, respectively.
This is the first study in csDMARD-IR patients with 
PsA to examine score changes in relation to MCIDs and 
normative values following treatment with tofacitinib. 
In another study, also reported in this issue, similar 
responses were reported by TNFi-IR patients with PsA 
receiving tofacitinib treatment over 6 months.45
A unique feature of this study is the evaluation of compo-
nents of the FACIT-Fatigue instrument that provide infor-
mation on the impact of tofacitinib on patients’ specific 
fatigue experience (perception and severity) and the 
impact on daily function. A limitation is that compar-
isons with placebo were limited to the 3-month place-
bo-controlled portion of the study. Also, this trial was not 
designed and was not powered to evaluate the non-inferi-
ority or superiority of tofacitinib as compared with adali-
mumab; therefore, comparisons should be interpreted 
cautiously. Furthermore, the majority of patients were 
receiving concomitant csDMARDs, and a similar standard 
of care may not be accessible in all countries, which may 
impact on the reproducibility of these results. In addi-
tion, use of ASQoL has not been specifically validated in 
axial PsA and may not be ideal for assessing peripheral 
PsA. Further PRO data for tofacitinib will be collected in 
the LTE study.
In conclusion, csDMARD-IR patients with PsA receiving 
tofacitinib 5 mg or 10 mg twice daily reported clinically 
meaningful improvements in PROs compared with 
placebo at month 3, which were maintained to month 12 
and ≥normative values in up to 39% of patients receiving 
tofacitinib. Patients receiving tofacitinib reported similar 
improvements to those receiving the active control adali-
mumab at the time points assessed. The results of this 
study provide scientific evidence to support decisions 
regarding clinical therapy and further support the use 
of JAK inhibition as a novel mechanism for treatment of 
PsA.
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